Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Chief Scientific Officer Alan J. Russell, sold 1,907 shares of common stock on August 12, 2025, for approximately $25,539. The shares were sold at an average price of $13.3924, with individual sales prices ranging from $13.36 to $13.49. According to InvestingPro data, the stock has gained 7.57% in the past week, though it remains significantly below its 52-week high of $38.12.
On the same day, Russell also exercised options to acquire 5,781 shares of Edgewise Therapeutics common stock at a price of $0. Additionally, Russell was granted 28,125 restricted stock units and options to purchase 168,750 shares of common stock. The company maintains strong financial health with a current ratio of 28.87, and five analysts have recently revised their earnings estimates upward. InvestingPro analysis indicates the stock is currently trading above its Fair Value, with additional insights available in the comprehensive Pro Research Report.
Following these transactions, Russell directly owns 23,400 shares of Edgewise Therapeutics, Inc., a company currently valued at $1.47 billion market cap with analyst price targets reaching as high as $51 per share.
In other recent news, Edgewise Therapeutics reported a narrower-than-expected loss for the second quarter of 2025. The company posted a quarterly loss of $0.34 per share, outperforming analysts’ expectations of a $0.42 per share loss. Edgewise maintains a strong cash position of approximately $594 million as of June 30, 2025, supporting its ongoing clinical programs. RBC Capital raised its price target for Edgewise Therapeutics to $49, maintaining an Outperform rating following the company’s earnings report. Meanwhile, Raymond James reiterated a Strong Buy rating with a $46 price target, noting that key catalysts, including the upcoming EDG-7500 Phase 2 CIRRUS-HCM Part D results, remain on track. Earlier trial data from Parts B/C in April 2025 showed promising efficacy, though concerns were noted about a potential atrial fibrillation signal in 14% of patients. These recent developments reflect the company’s continued progress and strategic positioning in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.